A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant

References

• Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252:252; http://dx.doi.org/10.1038/252252a0; PMID: 4424229
   PubMed Web of Science ®Google Scholar
• Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004; 22:1903 - 13; http://dx.doi.org/10.1016/j.vaccine.2003.11.008; PMID: 15121302
   PubMed Web of Science ®Google Scholar
• Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005; 10:711 - 9; PMID: 16341279
   PubMed Web of Science ®Google Scholar
• Kirby C, Gregoriadis G. Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes. Biotechnology 1984; 2:979 - 84; http://dx.doi.org/10.1038/nbt1184-979
   Web of Science ®Google Scholar
• Gammon B, Virden J, Berg J. The aggregation kinetics of an electrostatically stabilized dipalmitoyl phosphatidylcholine system. J Colloid Interface Sci 1989; 132:125 - 38; http://dx.doi.org/10.1016/0021-9797(89)90223-3
   Web of Science ®Google Scholar
• Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology 1966; 11:369 - 86; PMID: 5924622
   PubMed Web of Science ®Google Scholar
• Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:22 - 31; http://dx.doi.org/10.1016/j.bbamem.2005.10.011; PMID: 16321607
   PubMed Web of Science ®Google Scholar
• Snippe H, de Reuver MJ, Beunder JW, van der Meer JB, van Wichen DF, Willers JM. Delayed-type hypersensitivity in rabbits. Comparison of the adjuvants dimethyl dioctadecyl ammonium bromide and Freund’s complete adjuvant. Int Arch Allergy Appl Immunol 1982; 67:139 - 44; http://dx.doi.org/10.1159/000233004; PMID: 6173338
   PubMedGoogle Scholar
• Klinguer C, Beck A, De-Lys P, Bussat MC, Blaecke A, Derouet F, et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine 2001; 19:4236 - 44; http://dx.doi.org/10.1016/S0264-410X(01)00156-6; PMID: 11457550
   PubMed Web of Science ®Google Scholar
• Esposito E, Sebben S, Cortesi R, Menegatti E, Nastruzzi C. Preparation and characterization of cationic microspheres for gene delivery. Int J Pharm 1999; 189:29 - 41; http://dx.doi.org/10.1016/S0378-5173(99)00231-8; PMID: 10518683
   PubMed Web of Science ®Google Scholar
• Vangala A, Bramwell VW, McNeil S, Christensen D, Agger E-M, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 2007; 119:102 - 10; http://dx.doi.org/10.1016/j.jconrel.2007.01.010; PMID: 17331610
   PubMed Web of Science ®Google Scholar
• Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65:623 - 9; PMID: 9009322
   PubMed Web of Science ®Google Scholar
• Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791 - 5; http://dx.doi.org/10.1128/IAI.68.2.791-795.2000; PMID: 10639447
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72:1608 - 17; http://dx.doi.org/10.1128/IAI.72.3.1608-1617.2004; PMID: 14977968
   PubMed Web of Science ®Google Scholar
• Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen KT, et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005; 73:5817 - 26; http://dx.doi.org/10.1128/IAI.73.9.5817-5826.2005; PMID: 16113300
   PubMed Web of Science ®Google Scholar
• Hilgers LA, Snippe H, Jansze M, Willers JM. Combinations of two synthetic adjuvants: synergistic effects of a surfactant and a polyanion on the humoral immune response. Cell Immunol 1985; 92:203 - 9; http://dx.doi.org/10.1016/0008-8749(85)90001-2; PMID: 2581702
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121:216 - 26; http://dx.doi.org/10.1111/j.1365-2567.2007.02560.x; PMID: 17302734
   PubMed Web of Science ®Google Scholar
• Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009; 19:2 - 11; http://dx.doi.org/10.1080/08982100902726820; PMID: 19515003
   PubMed Web of Science ®Google Scholar
• Olds GR, Chedid L, Lederer E, Mahmoud AA. Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues. J Infect Dis 1980; 141:473 - 8; http://dx.doi.org/10.1093/infdis/141.4.473; PMID: 7373082
   PubMed Web of Science ®Google Scholar
• Pimm MV, Baldwin RW, Polonsky J, Lederer E. Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6′-dimycolate) and synthetic analogues. Int J Cancer 1979; 24:780 - 5; http://dx.doi.org/10.1002/ijc.2910240614; PMID: 544531
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249 - 54; http://dx.doi.org/10.1084/jem.178.6.2249; PMID: 7504064
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178:2243 - 7; http://dx.doi.org/10.1084/jem.178.6.2243; PMID: 8245795
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Bramwell VW, Coombes AGA, Perrie Y. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 2006; 40:30 - 8; http://dx.doi.org/10.1016/j.ymeth.2006.05.025; PMID: 16997711
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Bramwell VW, Kirby DJ, McNeil SE, Perrie Y. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. Eur J Pharm Biopharm 2010; 76:404 - 12; http://dx.doi.org/10.1016/j.ejpb.2010.09.008; PMID: 20884349
   PubMed Web of Science ®Google Scholar
• Christensen D, Foged C, Rosenkrands I, Nielsen HM, Andersen P, Agger EM. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim Biophys Acta 2007; 1768:2120 - 9; http://dx.doi.org/10.1016/j.bbamem.2007.05.009; PMID: 17555704
   PubMed Web of Science ®Google Scholar
• Christensen D, Kirby D, Foged C, Agger EM, Andersen P, Perrie Y, et al. alpha,alpha’-trehalose 6,6′-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim Biophys Acta 2008; 1778:1365 - 73; http://dx.doi.org/10.1016/j.bbamem.2008.01.013; PMID: 18261458
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008; 3:e3116; http://dx.doi.org/10.1371/journal.pone.0003116; PMID: 18776936
   PubMed Web of Science ®Google Scholar
• Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182:8047 - 55; http://dx.doi.org/10.4049/jimmunol.0801592; PMID: 19494330
   PubMed Web of Science ®Google Scholar
• Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010; 184:2756 - 60; http://dx.doi.org/10.4049/jimmunol.0904013; PMID: 20164423
   PubMed Web of Science ®Google Scholar
• Lang R, Schoenen H, Desel C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions. Immunobiology 2011; 216:1184 - 91; http://dx.doi.org/10.1016/j.imbio.2011.06.005; PMID: 21742403
   PubMed Web of Science ®Google Scholar
• Werninghaus K, Babiak A, Gross O, Hölscher C, Dietrich H, Agger EM, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009; 206:89 - 97; http://dx.doi.org/10.1084/jem.20081445; PMID: 19139169
   PubMed Web of Science ®Google Scholar
• Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One 2013; 8:e53531; http://dx.doi.org/10.1371/journal.pone.0053531; PMID: 23308247
   PubMed Web of Science ®Google Scholar
• Vangala AK, Kirby D, Rosenkrands I, Agger E-M, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 2006; 58:787 - 99; http://dx.doi.org/10.1211/jpp.58.6.0009; PMID: 16734980
   PubMed Web of Science ®Google Scholar
• Kirby DJ, Rosenkrands I, Agger E-M, Andersen P, Coombes AGA, Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008; 16:282 - 93; http://dx.doi.org/10.1080/10611860801900462; PMID: 18446607
   PubMed Web of Science ®Google Scholar
• Kirby DJ, Rosenkrands I, Agger E-M, Andersen P, Coombes AGA, Perrie Y. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 2008; 16:543 - 54; http://dx.doi.org/10.1080/10611860802228558; PMID: 18686124
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Bramwell VW, Perrie Y. Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics 2010; 2:91 - 104; http://dx.doi.org/10.3390/pharmaceutics2020091
   PubMedGoogle Scholar
• Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010; 142:180 - 6; http://dx.doi.org/10.1016/j.jconrel.2009.10.022; PMID: 19874860
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger E-M, Andersen P, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and immunogenicity of the vaccine. J Control Release 2010; 145:102 - 8; http://dx.doi.org/10.1016/j.jconrel.2010.03.027; PMID: 20381556
   PubMed Web of Science ®Google Scholar
• McNeil SE, Rosenkrands I, Agger EM, Andersen P, Perrie Y. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. J Pharm Sci 2011; 100:1856 - 65; http://dx.doi.org/10.1002/jps.22427; PMID: 21374619
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger E-M, Andersen P, et al. Comparison of the depot effect and immunogenicity of liposomes based on DDA, DC-Chol and DOTAP: Prolonged liposome retention mediates stronger Th1 responses. Molecular Pharmaceutics. Mol Pharm 2011; 8:153 - 61; http://dx.doi.org/10.1021/mp100208f; PMID: 21117621
   PubMed Web of Science ®Google Scholar
• Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, Christensen JP, et al. Vaccine adjuvants based on saturated quaternary ammonium lipids have different in vivo distribution kinetics and display distinct T cell-inducing capacity compared to their unsaturated analogues. J Control Release. J Control Release 2012; 160:468 - 76; http://dx.doi.org/10.1016/j.jconrel.2012.03.016; PMID: 22709414
   PubMed Web of Science ®Google Scholar
• Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010; 147:342 - 9; http://dx.doi.org/10.1016/j.jconrel.2010.08.012; PMID: 20727926
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 2011; 154:131 - 7; http://dx.doi.org/10.1016/j.jconrel.2011.05.019; PMID: 21640145
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066:29 - 36; http://dx.doi.org/10.1016/0005-2736(91)90246-5; PMID: 2065067
   PubMed Web of Science ®Google Scholar
• Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release 2012; 158:72 - 7; http://dx.doi.org/10.1016/j.jconrel.2011.10.012; PMID: 22032883
   PubMed Web of Science ®Google Scholar
• Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Blocking the depot-formation of cationic liposomal adjuvants at the injection site, by reducing their size and pegylating their surface, promotes rapid antibody production but reduced Th1 responses. J Control Release 2012; 164:331 - 7; http://dx.doi.org/10.1016/j.jconrel.2012.07.012; PMID: 22800572
   PubMed Web of Science ®Google Scholar
• Carstens MG, Camps MGM, Henriksen-Lacey M, Franken K, Ottenhoff THM, Perrie Y, et al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 2011; 29:4761 - 70; http://dx.doi.org/10.1016/j.vaccine.2011.04.081; PMID: 21565240
   PubMed Web of Science ®Google Scholar
• Glenny A, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:38 - 45
   Google Scholar
• Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010; 28:3588 - 94; http://dx.doi.org/10.1016/j.vaccine.2010.02.085; PMID: 20211692
   PubMed Web of Science ®Google Scholar
• Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007; 25:825 - 33; http://dx.doi.org/10.1016/j.vaccine.2006.09.039; PMID: 17014935
   PubMed Web of Science ®Google Scholar
• Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J 2012; 26:1272 - 9; http://dx.doi.org/10.1096/fj.11-184556; PMID: 22106367
   PubMed Web of Science ®Google Scholar